India and China probably give TEVA steep competition in terms of low cost generics, legal or otherwise. Difficult to believe that an outside generic company could be cost effective there.
Processing "natural" drugs such as opium, cannibus, and cocaine requires a lower skill set than producing reasonable copies or apparently valid labels for most regulated pharmaceutics.
Brazil is phasing out the use of similares, which are knockoffs of branded drugs that have not demonstrated bioequivalence to the corresponding brand. When similares are gone, the generic-drug market in Brazil will be a lot like the one in the US.
Market Data 
Markets 
AI
